Patel Engineering Board Approves Sale of Entire Stake in Ass...
Source: scanx.trade
14 May 2026
Metropolis Healthcare Limited's Nomination and Remuneration Committee convened on May 13, 2026, approving two significant employee benefit actions: the allotment of equity shares under its existing RSU plan and the grant of fresh stock benefits under its 2025 schemes. The meeting commenced at 09:00 a.m. (IST) and concluded at 12:10 p.m. (IST).
Allotment of Equity Shares Under MHL-RSU Plan, 2020
The committee approved the allotment of 4,200 equity shares against Restrictive Stock Units (RSUs) vested in and exercised by employees under the Metropolis – Restrictive Stock Unit Plan, 2020. The shares were issued at an exercise price of INR 2/- per share, with nil premium, aggregating to a total consideration of INR 8,400/-. The allotted shares rank pari-passu in all respects with the existing equity shares of the company.
The key details of the equity share allotment are summarised below:
Parameter: Details Date of Issue: May 13, 2026 Number of Shares Issued: 4,200 Exercise Price per Share: INR 2/- Premium per Share: Nil Total Consideration: INR 8,400/- Distinctive Numbers: 20,73,27,769 to 20,73,31,968 (both inclusive) Total Issued Shares After This Issue: 20,73,31,968 Total Issued Share Capital After This Issue: INR 41,46,63,936/- Lock-In Period: 1 year from date of allotment (50% of shares allotted to each RSU holder) Date of Expiry of Lock-In: May 13, 2027
The in-principle approvals for listing of these shares were received from BSE Limited vide letter no. DCS/ESOP/IP/RD/037/2026-27 dated April 23, 2026, and from the National Stock Exchange of India Limited vide letter no. NSE/LIST/54376 dated April 23, 2026.
Grant of Stock Benefits Under 2025 Schemes
In addition to the share allotment, the committee also approved the grant of stock benefits to eligible employees under two separate schemes introduced in 2025. These grants cover both RSU units and stock options, with structured vesting and exercise timelines.
The details of the stock benefit grants are as follows:
Parameter: RSU Plan, 2025 ESOP Plan, 2025 Units/Options Granted: 14,236 units 2,12,345 options Scheme Name: Metropolis – Restrictive Stock Units Plan, 2025 Metropolis – Employees Stock Options Plan, 2025 Compliant with SEBI (SBEB) Regulations, 2021: Yes Yes Total Shares Covered: 14,236 2,12,345 Exercise Price: INR 2/- per unit (face value) INR 375.62/- per option Minimum Vesting Period: 1 year, extendable up to four years 1 year, extendable up to four years Exercise Window: Within 5 years from date of vesting Within 5 years from date of vesting
Key Highlights
The allotted equity shares are issued under the MHL-RSU Plan, 2020, pursuant to RSUs vested and exercised by employees.
50% of the equity shares allotted to each RSU holder are subject to a lock-in period of one year from the date of allotment, expiring on May 13, 2027.
Fresh grants under the Metropolis – RSU Plan, 2025, and Metropolis – ESOP Plan, 2025, cover a combined total of 2,26,581 units and options for eligible employees.
Both 2025 schemes are compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
The ESOP options under the 2025 plan carry an exercise price of INR 375.62/- per option, while RSU units are priced at face value of INR 2/- per unit.
The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the requisite annexures have been submitted to the stock exchanges.
Metropolis Healthcare has notified the stock exchanges of a scheduled analyst and institutional investor meeting, pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 08, 2026, outlines the company's participation in an upcoming investor conference.
Investor Meeting Details
The meeting is scheduled to be held on May 27, 2026, as part of the 360 ONE Capital (B&K) Investor Conference. The following table summarises the key details of the interaction:
Parameter: Details Date: May 27, 2026 Time: 10:00 a.m. (IST) onwards Event: 360 ONE Capital (B&K) Investor Conference Type of Interaction: One to One & Group Meeting
Disclosure and Compliance
Metropolis Healthcare has confirmed that all discussions during the meeting will be based on publicly available information. The company has explicitly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction. The company has also noted that changes to the schedule may occur due to exigencies on the part of participants, the host, or the company itself.
The intimation has been filed by Kamlesh C Kulkarni, Head – Legal & Secretarial, and is available on the company's website at www.metropolisindia.com .
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.
Disclaimer:
The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.
